Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Learn how decades of #immunotherapy research is resulting in new cancer therapies: http://t.co/xMDUCNNN37 http://t.co/bAkC5xMmtH Via Krishan Maggon 
No comment yet.
Sign up to comment
Scoop.it!
Highlights
• CD154 is a co-stimulatory molecule known for its role in inflammatory and autoimmune diseases. •CD154 and its receptor, CD40 are expressed in many types of tumors. •The CD154/CD40 interaction is capable of inducing the proliferation and rescue from apoptosis of tumor cells. •CD154 activates anti-tumoral immunity, and by engaging CD40 may induce apoptosis of tumor cells. •The role of CD154 in cancer immunotherapy was demonstrated in animal models and clinically assessed in patients. Via Krishan Maggon
Krishan Maggon 's curator insight,
May 10, 2015 2:00 AM
doi:10.1016/j.ctrv.2015.03.007 Cancer Treatment Reviews Volume 41, Issue 5, May 2015, Pages 431–440 Laboratory-Clinic Interface Role of CD154 in cancer pathogenesis and immunotherapyGhada S. Hassan, John Stagg, Walid Mourad,
Scoop.it!
Tumor-specific immunotherapy holds the promise of eradicating malignant tumors with exquisite precision without additional toxicity to standard treatments. Via Krishan Maggon
Krishan Maggon 's curator insight,
April 20, 2015 11:43 PM
Review Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeuticsElias J Sayour12, Luis Sanchez-Perez3, Catherine Flores1 and Duane A Mitchell1* *Corresponding author: Duane A Mitchellduane.mitchell@neurosurgery.ufl.edu Author Affiliations 1Department of Neurosurgery, UF Brain Tumor Immunotherapy Program, University of Florida, Gainesville, Fl, USA 2Department of Pathology, Duke University Medical Center, Durham, NC, USA 3Division of Neurosurgery, Department of Surgery, Duke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, NC, USA For all author emails, please log on. Journal for Immunotherapy of Cancer 2015, 3:13 doi:10.1186/s40425-015-0058-0
Scoop.it!
Abstract Interleukin (IL)-15 is one of the most promising molecules to be used in antitumor immune therapy, as it is able to stimulate the main killer cells of both the innate and adaptive immune system. Although this cytokine can be used as a stand-alone immunotherapeutic agent, IL-15 will probably be most efficient in combination with other strategies to overcome high tumor burden, immune suppression of the tumor microenvironment and/or the short half-life of IL-15. In this review, we will discuss the combination strategies with IL-15 that have been tested to date in different animal tumor models, which include chemotherapy, other immunostimulatory cytokines, targeted therapy, adoptive cell transfer and gene therapy. In addition, we give an overview of IL-15 combination therapies that are currently tested in clinical studies to treat patients with hematological or advanced solid tumors. Via Krishan Maggon
Scoop.it!
Cancer immunotherapy utilizing Vγ9Vδ2 T cells has been developed over the past decade. A large number of clinical trials have been conducted on various types of solid tumors as well as hematological malignancies. Vγ9Vδ2 T cell-based immunotherapy can be classified into two categories based on the methods of activation and expansion of these cells. Although the in vivo expansion of Vγ9Vδ2 T cells by phosphoantigens or nitrogen-containing bisphosphonates (N-bis) has been translated to early-phase clinical trials, in which the safety of the treatment was confirmed, problems such as activation-induced Vγ9Vδ2 T cell anergy and a decrease in the number of peripheral blood Vγ9Vδ2 T cells after infusion of these stimulants have not yet been solved. In addition, it is difficult to ex vivo expand Vγ9Vδ2 T cells from advanced cancer patients with decreased initial numbers of peripheral blood Vγ9Vδ2 T cells. In this article, we review the clinical studies and reports targeting Vγ9Vδ2 T cells and discuss the development and improvement of Vγ9Vδ2 T cell-based cancer immunotherapy. Via Krishan Maggon
Krishan Maggon 's curator insight,
February 18, 2015 2:25 AM
Pharmaceuticals 2015, 8(1), 40-61; doi:10.3390/ph8010040 Reviewγδ T Cell Immunotherapy—A ReviewHirohito Kobayashi 1,* and Yoshimasa Tanaka 2,*1Transfusion Medicine and Cell Processing, Department of Urology, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan2Center for Therapeutic Innovation, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan*Authors to whom correspondence should be addressed; E-Mails: hirohitokobayashi-jua@umin.ac.jp (H.K.); ystanaka@nagasaki-u.ac.jp (Y.T.); Tel.: +81-3-3353-8111 (ext. 25035) (H.K.); +81-95-819-2890 (Y.T.); Fax: +81-3-5269-7685 (H.K.); +81-95-819-2420 (Y.T.).Academic Editor: Shin MineishiReceived: 6 January 2015 / Accepted: 2 February 2015 / Published: 12 February 2015- See more at: http://www.mdpi.com/1424-8247/8/1/40/htm#sthash.jOThc0Xd.dpuf
Scoop.it!
The better understanding of the mechanism in which Via Krishan Maggon
Krishan Maggon 's curator insight,
January 16, 2015 8:19 AM
OA, free pdf download
Hardy, B. and Raiter, A. (2013) New era in cancer immunotherapy: Twenty years to the discovery of monoclonal antibodies harnessing the immune system to eradicate tumors. Advances in Bioscience and Biotechnology, 4, 34-37. doi: 10.4236/abb.2013.44A005.
Advances in Bioscience and Biotechnology, 2013, 4, 34-37 ABB
|
Scoop.it!
There are many reasons to be excited by the science being presented at this year’s American Society for Clinical Oncology meeting. The data... Via Krishan Maggon
Scoop.it!
(Reuters) - Worldwide spending on cancer medicines reached $100 billion in 2014, an increase of 10.3 percent from 2013 and up from $75 billion five years earlier, according to IMS Health's Global Oncology... Via Krishan Maggon
Krishan Maggon 's curator insight,
May 5, 2015 3:55 AM
The US has 42% of the global cancer market. In the EU, Germany, France, UK, Italy and Spain are the top 5.
Medicines that target a specific protein or genetic mutation, as opposed to chemotherapies, now account for almost half of total U.S. cancer drug spending, IMS.
Forty-five new cancer drugs were launched between 2010 and 2014. But patients in no country had access in 2014 to all 37 launched between 2009 and 2013. The broadest access was seen in the United States, Germany and Britain, while fewer than half the new drugs were available in South Korea, Spain or Japan, the report said.
Five-year survival rates for many cancers are rising, the report found, with new immunotherapies, such as Merck's Keytruda and Bristol's Opdivo, holding the promise of improved survival with fewer side effects.
Krishan Maggon 's curator insight,
May 5, 2015 4:36 AM
The US has 42% of the global cancer market. In the EU, Germany, France, UK, Italy and Spain are the top 5.
Medicines that target a specific protein or genetic mutation, as opposed to chemotherapies, now account for almost half of total U.S. cancer drug spending, IMS.
Forty-five new cancer drugs were launched between 2010 and 2014. But patients in no country had access in 2014 to all 37 launched between 2009 and 2013. The broadest access was seen in the United States, Germany and Britain, while fewer than half the new drugs were available in South Korea, Spain or Japan, the report said.
Five-year survival rates for many cancers are rising, the report found, with new immunotherapies, such as Merck's Keytruda and Bristol's Opdivo, holding the promise of improved survival with fewer side effects.
Scoop.it!
Highlights
•Anticancer therapies alter the composition, phenotype, and function of immune cells.•The immune system is a major regulator of the success of anticancer therapy.•Immunotherapy and immunomodulatory agents often synergize with conventional therapies.•Resistance mechanisms following immunotherapy and immunodulatory agents are not fully defined.•Targeting both cancer cells and immune cells may be the key to fight metastasis.
Conventional anticancer therapies, such as chemotherapy, radiotherapy, and targeted therapy, are designed to kill cancer cells. However, the efficacy of anticancer therapies is not only determined by their direct effects on cancer cells but also by off-target effects within the host immune system. Cytotoxic treatment regimens elicit several changes in immune-related parameters including the composition, phenotype, and function of immune cells. Here we discuss the impact of innate and adaptive immune cells on the success of anticancer therapy. In this context we examine the opportunities to exploit host immune responses to boost tumor clearing, and highlight the challenges facing the treatment of advanced metastatic disease. Via Krishan Maggon
Krishan Maggon 's curator insight,
April 12, 2015 2:48 AM
Trends in Immunology Volume 36, Issue 4, p198–216, April 2015Feature Review Immune-mediated mechanisms influencing the efficacy of anticancer therapiesSeth B. Coffelt, Karin E. de VisserDivision of Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands DOI: http://dx.doi.org/10.1016/j.it.2015.02.006
Scoop.it!
MT @NatRevClinOncol A shed NKG2D ligand that promotes NK cell activation & #tumor rejection http://t.co/fjxcQRyDGS #immunotherapy #cancer
Abstract
Immune cells, including natural killer (NK) cells, recognize transformed cells and eliminate them in a process termed immunosurveillance. It is thought that tumor cells evade immunosurveillance by shedding membrane ligands that bind to the NKG2D activating receptor on NK cells and/or T cells, and desensitize these cells. In contrast, we show that in mice, shedding of MULT1, a high affinity NKG2D ligand, causes NK cell activation and tumor rejection. Recombinant soluble MULT1 stimulated tumor rejection in mice. Soluble MULT1 functions, at least in part, by competitively reversing a global desensitization of NK cells imposed by engagement of membrane NKG2D ligands on tumor-associated cells, such as myeloid cells. The results overturn conventional wisdom that soluble ligands are inhibitory, and suggest a new approach for cancer immunotherapy. Via Krishan Maggon
Gilbert C FAURE's insight:
potential harnessing of NK cells
Krishan Maggon 's curator insight,
March 6, 2015 6:34 AM
Published Online March 5 2015
< Science Express Index Read Full Text to Comment (0) Science DOI: 10.1126/science.1258867REPORT ANTITUMOR IMMUNITY A shed NKG2D ligand that promotes natural killer cell activation and tumor rejectionWeiwen Deng1, Benjamin G. Gowen1, Li Zhang1, Lin Wang1, Stephanie Lau1, Alexandre Iannello1, Jianfeng Xu1,Tihana L. Rovis2, Na Xiong3, David H. Raulet1,*+Author Affiliations 1Department of Molecular and Cell Biology, and Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA, 94720, USA.2Center for Proteomics University of Rijeka Faculty of Medicine Brace Branchetta 20, 51000 Rijeka, Croatia.3Department of Veterinary and Biomedical Sciences, Pennsylvania State University, 115 Henning Bldg, University Park, PA 16802, USA.↵*Corresponding author. E-mail: raulet@berkeley.edu
Scoop.it!
Highlights Via Krishan Maggon
Krishan Maggon 's curator insight,
January 30, 2015 8:49 AM
Molecular Immunology
Available online 13 January 2015 In Press, Corrected Proof — Note to users Review Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic ☆Connie P.M. Duonga, b, c, Carmen S.M. Yonga, b, Michael H. Kershawa, b, c, d, Clare Y. Slaneya, b, 1, , ,Phillip K. Darcya, b, c, d, 1, , doi:10.1016/j.molimm.2014.12.009 |
